

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Spider conservation in Europe: a review

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1771810> since 2023-01-26T13:56:00Z

Published version:

DOI:10.1016/j.biocon.2021.109020

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

***This is an author version of the contribution
published on:***

[EUROPEAN RESPIRATORY JOURNAL, vol. 45, issue 1, 2015,
10.1183/09031936.00130014]

The definitive version is available at::

[<http://erj.ersjournals.com/content/45/1/38.long>]

Long-term exposure to air pollution and lung function in adults: multicentre cohort study and meta-analysis, the ESCAPE project

Martin Adam^{1,2*}, Tamara Schikowski^{1,2,3*}, Anne Elie Carsin^{4*}, Yutong Cai⁵, Benedicte Jacquemin^{4,6,7}, Margaux Sanchez^{6,7}, Andrea Vierkötter³, Alessandro Marcon⁸, Dirk Keidel^{1,2}, Dorothee Sugiri³, Zaina Al Kanani⁵, Rachel Nadif^{6,7}, Valérie Siroux^{9,10}, Rebecca Hardy¹¹, Diana Kuh¹¹, Thierry Rochat¹², Pierre-Olivier Bridevaux¹², Marloes Eeftens^{1,2,13}, Ming-Yi Tsai^{1,2}, Simona Villani¹⁴, Harish Chandra Phuleria^{1,2}, Matthias Birk¹⁵, Josef Cyrus^{15,16}, Marta Cirach⁴, Audrey de Nazelle¹⁷, Mark J Nieuwenhuijsen⁴, Bertil Forsberg¹⁸, Kees de Hoogh⁵, Christophe Declercq¹⁹, Roberto Bono²⁰, Pavilio Piccioni²¹, Ulrich Quass²², Joachim Heinrich¹⁵, Deborah Jarvis^{5,23}, Isabelle Pin^{9,10,24}, Rob Beelen¹³, Gerard Hoek¹³, Bert Brunekreef^{13,25}, Christian Schindler^{1,2}, Jordi Sunyer^{4#}, Ursula Krämer^{3#}, Francine Kauffmann^{6#}, Anna L Hansell^{5,26#}, Nino Künzli^{1,2#}, Nicole Probst-Hensch^{1,2#}. *contributed equally; # Steering Committee of ESCAPE Work Package 4 on Respiratory Health in Adults.

Corresponding Author:

Prof. Dr. Nicole Probst-Hensch
Head Unit Chronic Disease Epidemiology
Swiss Tropical and Public Health Institute
Socinstrasse 57, P.O. Box, 4002 Basel, Switzerland
PHONE: 0041-61-284 83 78
FAX: 0041-61-284 81 05
EMAIL: Nicole.Probst@unibas.ch

¹ Swiss Tropical and Public Health Institute, 4002 Basel

² University of Basel, Switzerland;

³ Leibniz Research Institute for Environmental Medicine (IUF), 40225 Düsseldorf, Germany

⁴ Centre for Research in Environmental Epidemiology (CREAL), 08003 Barcelona, Spain

⁵ MRC-PHE Centre for Environment and Health, Dept of Epidemiology and Biostatistics, School of Public Health, Imperial College London, W2 1PG London, UK

⁶ Inserm, Centre for research in Epidemiology and Population Health (CESP), U1018, Respiratory and Environmental Epidemiology Team, 94807, Villejuif, France

⁷ Univ Paris-Sud, UMRS 1018, 94807, Villejuif, France.

⁸ Unit of Epidemiology and Medical Statistics, Department of Public Health and Community Medicine, University of Verona, 37134 Verona, Italy

⁹ Inserm U823, Environmental Epidemiology Applied to Reproduction and Respiratory Health team, 38042 Grenoble, France;

¹⁰ Univ Joseph Fourier, 83041 Grenoble, France

¹¹ MRC University Unit for Lifelong Health & Ageing at University College London WC1E 6BT, UK

¹² Division of Pulmonary Medicine, University Hospitals of Geneva, 1205 Geneva, Switzerland

¹³ Institute for Risk Assessment Sciences, Utrecht University, 3508 TD Utrecht, The Netherlands

¹⁴ Unit of Biostatistics and Clinical Epidemiology Department of Public Health, Experimental and Forensic Medicine University of Pavia, 27100 Pavia, Italy.

¹⁵ Helmholtz Zentrum, München & German Research Centre for Environmental Health, Institute of Epidemiology I, 85764 Neuherberg, Germany

¹⁶ Environmental Science Center, University Augsburg, 86150 Augsburg, Germany

¹⁷ Centre for Environmental Policy, Imperial College London, London SW7 1NA, UK

¹⁸ Environmental and Occupational Medicine, Department of Public Health and Clinical Medicine, Umeå University, SE-901 85 Umeå, Sweden

¹⁹ French Institute for Public Health Surveillance, 94415 Saint-Maurice, France.

²⁰ Department of Public Health and Pediatrics, University of Turin, 10126 Turin, Italy

²¹ SC Pneumologia CPA ASL 4 Turin, 10154 Turin, Italy

²² Air Quality and Sustainable Nanotechnology, IUTA Institut für Energie- und Umwelttechnik e.V., 47229 Duisburg, Germany

²³ Department of Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College London, London SW7 2AZ, UK

²⁴ Pédiatrie, CHU de Grenoble, 38700 La Tronche, France.

²⁵ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands

²⁶ Public Health and Primary Care Directorate, Imperial College Healthcare NHS Trust, London SW7 2AZ, UK

Abstract

Objectives To investigate the association of long-term exposure to ambient air pollution with lung function level and change in adult participants from five cohorts in the European Study of Cohorts for Air Pollution Effects (ESCAPE).

Design Multicentre cohort study and meta-analysis of the results.

Setting Centres from five cohorts in Belgium, France, Germany, Italy, Spain, Sweden, Switzerland and the United Kingdom

Participants 7613 participants undergoing spirometry twice within a decade were enrolled.

Main outcome measures Residential exposure to nitrogen oxides (NO₂, NO_x) and particulate matter (PM) was modeled and traffic indicators were assessed in a standardized manner. The spirometric parameters FEV₁ and FVC were considered as outcomes. Cohort-specific analyses were performed by mixed linear regression adjusting for sex, age, height, BMI, education and smoking status. Cohort-specific results were combined using meta-analysis.

Results We did not observe an association of air pollution with the longitudinal change in lung function, but we observed that a 10 µg/m³ increase in NO₂ exposure was associated with lower levels of FEV₁ (-14.0 mL (95%CI:-25.8,-2.1)) and FVC (-14.9 mL (-28.7,-1.1)). An increase of 10 µg/m³ in PM₁₀, but not other PM metrics (PM_{2.5}, PM coarse, PM absorbance), was associated with a lower level of FEV₁ (-44.6mL (-85.4,-3.8)) and FVC (-59.0mL (-112.3,-5.6)). Higher traffic load at home address was also significantly associated with lower levels of FEV₁. The associations were particularly strong in obese persons.

Conclusions This study adds to the evidence for an adverse association of ambient air pollution with lung function in adults at very low levels in Europe.

Introduction

Lung function specifically, forced vital capacity [FVC] and forced expiratory volume in one second [FEV₁]) are objectively measurable quantitative parameters of respiratory health. It is an early indicator of respiratory and systemic inflammation, and associated with cardiorespiratory morbidity and mortality. Acute effects of air pollution on lung function at levels currently observed in Western Europe at all ages are well established. To what extent long-term exposure to air pollution results in lower lung function remains less clear¹. Evidence for long-term pollution effects on slowing down lung function growth in children is strong, while data for chronic lung function effects in adults is more limited and mostly restricted to susceptible populations¹⁻³. In the largest⁴ of the predominantly cross-sectional studies⁴⁻⁷, Forbes et al. found increases in 10 µg/m³ of PM₁₀ associated with a decrease of about 3% in FEV₁. At 1st spirometry SAPALDIA found an increase of 10 µg/m³ in annual mean concentration of PM₁₀ was associated with 3.4% lower FVC and 1.6% lower FEV₁⁵. The SALIA study of women showed negative associations of PM₁₀ concentrations with FEV₁ and FVC (5.1% and 3.7% respectively, per 7 µg/m³ 5-year annual mean PM₁₀)⁷. The strongest indirect evidence for adverse long-term pollution effects on lung function decline in adults comes from a single follow-up study demonstrating that improvements in PM₁₀ exposure over a period of eleven years attenuated the age-related decrease in respiratory function⁸. A more recent study found cumulative long-term exposure to ambient PM₁₀ and ozone associated with both FEV₁ and FVC decline in an elderly population and suggested an increased susceptibility among frail persons⁹. Statistically significant associations were also reported for NO₂ and traffic exposure^{5,7}.

The ESCAPE project (European Study of Cohorts for Air Pollution Effects) combined data from over 30 cohort studies and modeled home outdoor levels of air pollution in a standardized manner¹⁰. This paper makes use of five health cohorts with spirometry data, to investigate the association of air pollution with lung function level and age-related decline.

Methods

Design and Participants

This study is an analysis of cohort data obtained by ESCAPE to investigate the long term effects of exposure to air pollution on respiratory health in Europe and a meta-analysis of the cohort specific results. The present study included 5 European cohorts/studies from eight countries with information on lung function and the most important potential confounders. The analyses were based on subpopulations from European Community Respiratory Health Survey (ECRHS), French Epidemiological study on Genetics and Environment of Asthma (EGEA), the National Survey of Health and Development (NSHD), Study on the influence of Air pollution on Lung function, Inflammation and Aging (SALIA) and Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults (SAPALDIA) (Supplemental Material: Methods (Cohorts) and Supplemental Table 1). Criteria for inclusion of cohort participants in the present analyses were: at least 20 years old; pre-bronchodilation spirometry data from two different time points approximately one decade apart (referred to as first (1st) and second (2nd) spirometry, respectively); non-missing information for the primary covariates used in the main models (questionnaire-based variables: age, sex, smoking status, education; measured variables: height and BMI (derived from measured height and weight); living in cohort areas selected for ESCAPE monitoring

campaigns; and successfully assigned home outdoor exposure estimates for NO₂/NO_x/Traffic indicators (referred to as NO-population) and PM metrics (a subsample of the NO population, referred to as PM-population). Of 13259 participants with 1st and 2nd spirometry living in ESCAPE monitoring areas, 7615 and 4233, respectively provided complete datasets towards analysis of NO₂/NO_x/Traffic indicators and PM metrics (Supplemental Figures 1a-e).

Exposure data

ESCAPE exposure assessment was described before and is based on fully standardized measurement and modeling protocols (<http://www.escapeproject.eu/manuals/>)¹⁰⁻¹³. The general concept consisted in the individual assignment of outdoor annual mean concentrations of a pre-defined set of air pollution markers to each participant's residential address.

ESCAPE monitoring campaigns in different study areas between 2008-2011 measured NO₂ and NO_x as well as in a smaller number of areas PM_{2.5}, PM₁₀, the coarse fraction of PM (PM₁₀ minus PM_{2.5}) and light absorbance of PM_{2.5}. Within each study area, concentration levels were monitored at 40 (NO₂, NO_x) or 20 (PM measures) predefined sites during three seasonally distinct 2-week periods^{13, 14}. Land use regression (LUR) models were developed to explain the spatial variation of measured annual average air pollutant concentration within each study area. This technique combines measurement data with Geographic Information System (GIS) derived land-use and traffic information to predict annual pollution concentration at sites without measurements and was used to estimate annual pollutant concentrations at each participant's residential address^{10, 11}.

In addition to pollutant concentrations, we also used as indicators of local exposure to traffic related pollutants traffic intensity at the road nearest to a participant's home and total traffic load on major roads in a 100 meter buffer of the home. Traffic measures were often used in other studies as proxies of exposure to near-road pollutants such as e.g. ultrafine particles or NO, which exponentially decay within 100-150 m from the curb side.

To address the time discrepancy between air pollution monitoring (2008-2011) and health examination (spirometry conducted between 1985-2010; Supplemental Table 2), sensitivity analyses replaced ESCAPE exposure estimates with estimates back extrapolated to the time of 1st and 2nd spirometry (except for the time a. of 1st spirometry in ECRHS and EGEE, where no historical data was available and b. 2nd up spirometry in NSHD and SALIA conducted between 2006-2010, sufficiently close to the ESCAPE monitoring campaigns). During the past decades, air quality has in general improved. Given the lack of historic LUR models, ESCAPE could not individually estimate within-city contrasts of air quality for these past years. Instead, where available, annual means from fixed site monitoring stations were used to derive past annual mean concentrations for pollutants with available historic data (NO₂ and PM₁₀, only). For each study participant's home address the back extrapolated concentration was obtained by multiplying the modeled ESCAPE annual mean concentration with the ratio between average annual concentrations as derived from the routine monitoring site(s) for the period in the past and for the ESCAPE measurement period time (for details see in <http://www.escapeproject.eu/manuals/>)¹². The procedures applied assumed that the

within-city spatial contrasts remained proportional over time. Gulliver et al confirmed the validity of this assumption for the United Kingdom ¹⁵.

Lung Function Metrics and Outcomes

FEV₁ and FVC were used as outcome metrics. In cross-sectional analysis, we focused on lung function measured at the 2nd spirometry (time point closest to ESCAPE air pollution monitoring). Change in lung function between 1st and 2nd spirometry was assessed as both annual lung function change (mL/year) and annual change in lung function as a percentage of the 1st spirometry value (%/year) (Supplemental Material: Methods (Lung Function Metrics and Outcomes)), with a negative value representing a decline. Data presented are restricted to absolute change as results did not materially differ for percent (%) change as outcome.

Statistical analyses

Firstly, study specific data were analyzed separately following identical analytical procedures. Associations of air pollutants with lung function metrics were estimated using multivariable mixed linear regression models with a random intercept for ESCAPE areas with their own exposure monitoring and modeling. Three confounder models were specified a priori, adjusting for an increasing number of covariates selected on the basis of previous cohort studies of air pollution and lung function and the availability of data for most cohorts, excluding missing values on any of the covariates. The covariate definitions were standardized across studies (see Supplemental Material: Methods). In the absence of materially different effect estimates derived from models adjusting for additional covariates, we chose as main analytic model the one adjusting for age (years), age squared, height (cm), sex, body mass index (BMI, kg/m²), educational level (low as reference, medium, high), and smoking status (never as reference, ever). Models analyzing traffic exposure indices were additionally adjusting for background NO₂ concentrations. The traffic indicator coefficients are thus assumed to reflect the impact of pollutants highly concentrated along the roads. The median of traffic indicator values across all studies was chosen as cutoff for dichotomizing the continuous traffic exposure (≤ 5000 and >5000 [cars per day] for traffic intensity on the nearest major road; ≤ 500 and >500 [cars-km driven per day] for the traffic intensity on major roads in a 100m buffer) (Supplemental Material: Methods (Statistical Models)). Traffic variables were also analyzed on a continuous scale but this did not produce meaningful results.

Secondly, cohort specific overall and stratum-specific effect estimates obtained by mixed linear regression models were meta-analyzed (Supplemental Material: Methods (Meta-analysis)).

A pre-defined set of variables considering previous evidence and cohort differences was tested for effect modification. We compared the summary estimates of the two opposite subgroups (females vs. males; not obese vs. obese; never vs. ever smokers; never asthma vs. ever asthma) using a Chi²-test with one degree of freedom. In sensitivity analyses we restricted the analytic model to non-movers and participants aged 30+ (age at 1st spirometry).

Statistical analyses were performed using STATA, version 12 (StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP).

Results

Study characteristics. Table 1 provides a description of the cohort specific study populations. The average age of the cohorts at the time of 2nd spirometry ranged from 43 years (ECRHS) to 73 years (SALIA). The SALIA population, consisting exclusively of women, exhibited the lowest mean levels of FEV₁ (2.20 L) and FVC (2.91 L) (see Table 1) (for the smaller PM subpopulation and for the cohort-specific lung function distributions stratified by sex, smoking and asthma status see Supplemental Table 3).

Air pollution exposure. Table 2 shows the distribution of the air pollution metrics for each study area. Variance explained by LUR models varied between 55% and 92% for NO₂ and between 68% and 90% for PM₁₀ (Supplemental Table 4). Mean exposure was lowest for all air pollution metrics in NSHD. Within-study contrasts were smallest for SALIA and SAPALDIA reflecting the restricted geographic region covered (Supplemental Table 5). The study specific correlations between the exposure metrics were generally highest between NO₂ and NO_x (rho of 0.90-0.98), but moderate to low between pollutants and traffic indicators (Supplemental Table 6). ESCAPE derived exposures were highly correlated with the exposures backextrapolated to the time of the 2nd spirometry ($\rho_{\text{NO}_2} \geq 0.94$; $\rho_{\text{PM}_{10}} \geq 0.91$), but less strongly correlated with exposures backextrapolated to the 1st spirometry ($0.56 \leq \rho_{\text{NO}_2} \leq 0.92$; $0.47 \leq \rho_{\text{PM}_{10}} \leq 0.74$).

Association between air pollution and lung function. The main meta-analysis results for associations of each air pollution metric with level and change of lung function are presented in Table 3. No associations between any exposure metric and lung function decline were present, irrespective of covariate adjustment and subgroup (gender, obesity, asthma, smoking). Looking at levels of lung function cross-sectionally, we found higher NO₂ and NO_x exposures to be associated with lower levels of FVC and FEV₁. An increase of 10 µg/m³ in NO₂ exposure was associated with a -14.0 mL lower level of FEV₁ (95%CI: -25.8, -2.1) and -14.9 mL lower level of FVC (-28.7, -1.1) (Table 3, Figures 1 and 2). An increase of 20 µg/m³ in NO_x exposure was associated with a lower level of FEV₁ by -12.9 mL (-23.8, -2.0) and of FVC by -13.3 mL (-25.9, -0.7) and an increase of 10 µg/m³ in PM₁₀ was associated with a lower level of FEV₁ (-44.6mL (-85.4, -3.8)) and FVC (-59.0mL (-112.3, -5.7)) (Table 3). The other PM metrics were not associated with lung function level. Higher traffic load on major roads in a 100m buffer from residential address was associated with lower levels of FEV₁ (-32.34mL (-59.30, -5.38)).

Associations observed for NO₂ and PM₁₀ with FEV₁ and FVC at 2nd spirometry remained largely unaltered when ESCAPE exposure estimates of NO₂ and PM₁₀ in ECRHS, EGEA and SAPALDIA were replaced with NO₂ and PM₁₀ estimates backextrapolated to the time point of the 2nd spirometry. The inverse association between PM₁₀ and FVC became stronger and statistically significant (Supplemental Table 7).

In subgroup analysis, the NO₂ and NO_x (data not shown) associations with FEV₁ and FVC were particularly observed in obese participants (FEV₁: Figures 3 and 4, FVC: Supplemental Figures 2 and 3) (p-values for heterogeneity obese vs. non-obese: p=0.098 (NO₂/FEV₁) (Figures 3 and 4); p=0.026 (NO₂/FVC) (Supplemental Figures 2 and 3), p=0.050 (NO_x/FVC). All other tested factors (gender, smoking and asthma status) showed no or only weak evidence for

modification of the air pollution lung function associations (NO₂: Supplemental Table 8). The effect modification by obesity was also evident in gender-stratified analyses, with substantially stronger inverse NO₂ and NO_x associations with FEV₁ and FVC, in both obese women and men (NO₂: Supplemental Table 9).

In sensitivity analysis, looking at non-movers and participants aged 30 years or more, we did not find a particular difference to the observed main associations (Supplemental Table 10).

Discussion

This study in adults contributes to the evidence of long-term exposure to ambient air pollution being associated with the level of lung function. The meta-analysis was based on individual-level exposure assessment standardized across different cities and regions in Europe. Impaired lung function characterized by reduced FEV₁, a powerful marker of future morbidity and mortality¹⁶, exhibited the most consistent association with different pollution metrics. It was inversely related to nitrogen oxides, PM₁₀ as well as traffic load at the residential address. Our data suggest that obese persons are particularly sensitive to air pollution.

Comparison with other studies

Results from previous cross-sectional studies predominantly relied on exposure measured at the level of a few communities. They point to an inverse association of adult lung function with air pollution and traffic load^{1,6}. But as the measurement and meaning of specific pollution metrics differs between studies their comparative relevance remains inconclusive. This also applies to the current study. According to the site-specific differences in correlations between exposure metrics (Supplemental Table 6) they capture different sources of air pollution and thereby different components. The absence of associations with most of the PM metrics may additionally be rooted in the more limited sample size. PM measurements were only performed in a restricted number of centers. NO₂ which characterizes the spatial variation of traffic related air pollution has been linked with stronger lung function impairment depending on the parameter studied, but evidence for PM effects to be stronger has also been published^{3,7}.

The interaction between air pollution exposure and obesity on lung function parallels a recent SAPALDIA report and adds evidence to the interdependence of the two important global epidemics of environmental pollution and obesity¹⁷. Many studies have demonstrated an association between obesity and lung function. Lung function improves after weight loss in obese persons, and weight gain is associated with lung function decline in asthmatics and in the general population¹⁷⁻¹⁹. The mechanical effect of excess body fat on lung volumes and airway caliber is well accepted¹⁸. In addition, inflammatory pathways may play a role, as overweight is associated with an underlying state of oxidative stress and inflammation^{17,20}. Air pollution and obesity seemingly have more than additive effects on systemic inflammation^{21,22}. In animal models, ozone-induced pulmonary injury and inflammation were greater in obese versus lean mice^{23,24}. In humans, acute ozone effects on lung function were more prominent among obese^{25,26}.

The null finding investigating the association of air pollution with the change in lung function is consistent with a previous report from the ECRHS cohort²⁷, but extends the finding to older cohorts. In light of the positive findings for the cross-sectional associations, this null finding may be surprising. Cross-sectional differences are expected to result at least in part from differences in age-related decline. Based on the current results it seems premature to conclude that long-term exposure to air pollution does not affect FEV₁ and FVC decline.

Strengths and weaknesses

Our study benefits from a large number of observations, and the multi-centric design across different European regions, which cover a broad range of different types of environment and climates and a wide age range of participants. Furthermore, the individual-level exposure assessment was harmonised, a common study protocol of exposure and outcome definition was developed and the analytic approach was standardised. However, this study has also several limitations.

Several methodological issues related to outcome and exposure assessment may have biased the longitudinal association. Data from only two spirometry time points and from spirometries conducted in different seasons and times of the day may have decreased the precision in estimating lung function decline. As common in long-term lung function studies, spirometry devices had to be updated with new software or replaced during follow-up. Such changes can be an inherent source of differences in the measured lung function and its temporal change²⁸. The inherent limitations in exposure assessment are also amplified in the longitudinal analyses. Most importantly, back extrapolation of residential pollution levels is of prime relevance to properly characterize exposure at 1st spirometry, and then derive the change in exposure over time. Uncertainties with the back extrapolated values may be substantial and if unrelated to the true exposure, may bias findings towards the null. In addition LUR models have inherent limitations. Cross-validation of the LUR's varied across regions^{10, 11} and performance of models based on 20 or 40 measurement sites may be overestimated^{29, 30}.

Additional limitations of the study beyond back extrapolation include the non-availability of information on short-term exposure at the time of spirometry for a sufficient number of sites and pollution metrics. Adjustment for short-term exposure in SAPALDIA did not alter the associations. Heterogeneity of study populations poses a challenge to meta-analysis and makes it difficult to exclude residual confounding and unrecognized effect modification. The associations were not sensitive to the SALIA study consisting exclusively of women and exhibiting the lowest mean levels of lung function (Supplemental Figures 4 and 5 for associations of NO₂ with FEV₁ and FVC in women). Non-participation at follow-up of subjects with low lung function may bias observed associations or limit their generalizability. In SAPALDIA subjects with better lung function were more likely to participate at the 2nd spirometry. But sensitivity analyses using inverse probability weighting to account for non-participation did not alter associations between air pollution and lung function⁸.

Conclusion

The current study, which includes a large number of observations from different regions, environments and climates in Europe, and standardized exposure assessment, provides firm

support to an adverse association between ambient air pollution and lung function in adults. Inverse associations could be observed at very low air pollution levels in Europe. The policy relevance of these findings is further strengthened by the observation that obese persons may be particularly susceptible.

What is already known on this topic

- Acute effects of air pollution on lung function at levels currently observed in Western Europe at all ages are well established.
- The association between long term exposure to air pollution and lower lung function in adults remains less clear.

What this study adds

- This paper contributes important evidence towards the EU air quality policy debates.
- In the largest European wide meta-analysis of its kind, we report associations of NO₂, NO_x and PM₁₀ with lung function.
- The study provides suggestive evidence for an increased susceptibility of obese persons, pointing to the interdependence of environmental and health policies.

Role of the funding source

The funding source had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. The authors had full access to all data and had final responsibility for the decision to submit the paper.

Competing interests

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethics committee approval

All included cohort studies were approved by the institutional medical ethics committees and undertaken in accordance with the Declaration of Helsinki. Each cohort study followed the rules for ethics and data protection set up in the country in which they were based.

Transparency statement

The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.”

Data sharing

Meta-analytic data and statistical code are available from the corresponding author.

Copyright for authors

“The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish,

reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above”.

Open access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY- NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/3.0/>.

Contributors

MA, NPH drafted the manuscript; BB, BF, JS, UK, FK, AH, NK, NPH contributed to the design of the study; MA, TS, AEC, AM, BJ, VS, CS, JS, UK, FK, AH, NK, NPH contributed to the data analysis plan; MA, TS, AEC; YC, BJ, MS, AV, AM, DK, SD, ZAK, GH, contributed to the statistical script and data analysis; RN, VS, RH, DK, TR, POB, RB, PP, JH, DJ, IP, JS, UK, FK, AH, NK, NPH provided local cohort data; DS, ME, MYT, SV, HCP, MB, JC, MC, ADN, MJN, BF, KDH, CD, UQ, RB, GH, BB contributed to exposure assessment; all co-authors contributed to the interpretation of the results and have read, revised and approved the final version of the submitted manuscript.

Funding

The research leading to these results has received funding from the European Community's Seventh Framework Program (FP7/2007-2011) under grant agreement number: 211250.

ECRHS was supported by the European Commission, as part of their Quality of Life program. The coordination of ECRHS II was supported by the European Commission, as part of their Quality of Life programme. The following bodies funded the local studies in ECRHS II in this article.

Albacete-Fondo de Investigaciones Santarias (grant code: 97/0035-01, 13 99/0034-01, and 99/0034-02), Hospital Universitario de Albacete, Consejería de Sanidad. Antwerp-FWO (Fund for Scientific Research)- Flanders Belgium (grant code: G.0402.00), University of Antwerp, Flemish Health Ministry.

Barcelona-Fondo de Investigaciones Sanitarias (grant code: 99/0034-01, and 99/0034-02), Red Respira (RTIC 03/11 ISC IIF). Ciber of Epidemiology and Public Health has been established and founded by Instituto de Salud Carlos III.

Erfurt-GSF–National Research Centre for Environment & Health, Deutsche Forschungsgemeinschaft (DFG) (grant code FR 1526/1-1).

Galdakao-Basque Health Department.

Grenoble-Programme Hospitalier de Recherche Clinique-DRC de Grenoble 2000 no.2610, Ministry of Health, Direction de la Recherche Clinique, Ministère de l'Emploi et de la Solidarite, Direction Generale de la Sante, CHU de Grenoble, Comité des Maladies Respiratoires de l'Isere.

Ipswich and Norwich-National Asthma Campaign (UK).

Huelva-Fondo de Investigaciones Sanitarias (FIS) (grant code: 97/0035-01, 99/0034-01, and 99/0034-02).

Oviedo-Fondo de Investigaciones Santarias (FIS) (grant code: 97/0035-01, 99/0034-01, and 99/0034-02).

Paris-Ministere de l'Emploi et de la Solidarite, Direction Generale de la Sante, UCBPharma (France), Aventis (France), Glaxo France, Programme Hospitalier de Recherche Clinique-DRC de Grenoble 2000 no. 2610, Ministry of Health, Direction de la Recherche Clinique, CHU de Grenoble.

Measurements and models for PM in Grenoble (ECRHS) were funded by Region Rhône-Alpes.

Pavia-Glaxo, Smith & Kline Italy, Italian Ministry of University and Scientific and Technological Research (MURST), Local University Funding for Research 1998 & 1999 (Pavia, Italy).

Turin-ASL 4 Regione Piemonte (Italy), AO CTO/ICORMA Regione Piemonte (Italy), Ministero dell'Università e della Ricerca Scientifica (Italy), Glaxo Wellcome spa (Verona, Italy).

Umeå-Swedish Heart Lung Foundation, Swedish Foundation for Health Care Sciences & Allergy Research, Swedish Asthma & Allergy Foundation, Swedish Cancer & Allergy Foundation.

Verona-University of Verona; Italian Ministry of University and Scientific and Technological Research (MURST); Glaxo, Smith & Kline Italy.

EGEA is funded in part by PHRC-Paris, PHRC-Grenoble, ANR 05-SEST-020-02/05-9-97, ANR-06-CEBS, ANRCES- 2009, Région Nord Pas-de-Calais, Merck Sharp & Dohme (MSD).

NSHD and Professors Hardy and Kuh are supported by core funding and grant funding (U1200632239 and U12309272) from the UK Medical Research Council. We acknowledge the NSHD participants and the NSHD scientific and data collection teams.”

SALIA received funds from the German state (NRW) and federal Ministries of the Environment. The follow-up investigation was funded by the DGUV (German statutory accident assurance) VT 266.1.

SAPALDIA received funds from the Swiss National Science Foundation (grants no 33CSCO-134276/1, 33CSCO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099), the Federal Office for Forest, Environment and Landscape and several Federal and Cantonal authorities.

Acknowledgements

We acknowledge the support of an external advisory board consisting of Mike Jerrett (UC Berkeley, Berkeley CA), Joel Kaufman (University of Washington, Seattle WA), Ross Anderson (King’s College London UK), Michal Krzyzanowski (WHO Bonn, Germany), Aaron Cohen (Health Effects Institute Boston MA).

We thank all study members and staff involved in data collections in each cohort and also the respective funding bodies for ECRHS, EGEA, NSHD, SALIA and SAPALDIA:

ECRHS

The ECRHS data incorporated in this analysis would not have been available without the collaboration of the following individuals and their research teams.

ECRHS Co-ordinating centre: P Burney, D Jarvis, S Chinn, J Knox (ECRHS II), C Luczynska⁺, J Potts.

Steering Committee for ECRHS II: P Burney, D Jarvis, S Chinn, J.M Anto, I.Cerveri, R.deMarco, T.Gislason, J.Heinrich, C. Janson, N. Kunzli, B. Leynaert, F. Neukirch, T. Rochat, J. Schouten, J. Sunyer; C. Svanes, P. Vermeire⁺, M. Wjst.

Principal Investigators and Senior Scientific Teams for ECRHS II: Australia: Melbourne (M Abramson, R Woods, EH Walters, F Thien), Belgium: South Antwerp & Antwerp City (P Vermeire⁺, J Weyler, M Van Sprundel, V Nelen), Denmark: Aarhus (EJ Jensen), Estonia: Tartu (R Jogi, A Soon), France: Paris (F Neukirch, B Leynaert, R Liard, M Zureik), Grenoble (I Pin, J Ferran-Quentin), Bordeaux (A Taytard, C Raheison), Montpellier (J Bousquet, P Demoly)Germany: Erfurt (J Heinrich, M Wjst, C Frye, I Meyer) Hamburg (K Richter),Iceland: Reykjavik (T Gislason, E Bjornsson, D Gislason, T Blondal, A Karlsdottir), Italy: Turin (M Bugiani, P Piccioni, E Caria, A Carosso, E Migliore, G Castiglioni), Verona (R de Marco, G Verlato, E Zanolin, S Accordini, A Poli, V Lo Cascio, M Ferrari), Pavia (A Marinoni, S Villani, M Ponzio, F Frigerio, M Comelli, M Grassi, I Cerveri, A Corsico),Netherlands: Groningen & Geleen (J Schouten, M Kerkhof), Norway: Bergen (A Gulsvik, E Omenaas, C Svanes, B Laerum), Spain: Barcelona (JM Anto, J Sunyer, M Kogevinas, JP Zock, X Basagana, A Jaen, F Burgos), Huelva (J Maldonado, A Pereira, JL Sanchez), Albacete (J Martinez-Moratalla Rovira, E Almar), Galdakao

(N Muniozguren, I Urritia), Oviedo (F Payo), Sweden: Uppsala (C Janson, G Boman, D Norback, M Gunnbjornsdottir), Goteborg (K Toren, L Lillienberg, AC Olin, B Balder, A Pfeifer-Nilsson, R Sundberg), Umea (E Norrman, M Soderberg, K Franklin, B Lundback, B Forsberg, L Nystrom), Switzerland: Basel (N Kunzli, B Dibbert, M Hazenkamp, M Brutsche, U Ackermann-Liebrich); UK: Norwich (D Jarvis, B Harrison), Ipswich (D Jarvis, R Hall, D Seaton), USA: Portland (M Osborne, S Buist, W Vollmer, L Johnson).

†Deceased

The excellent fieldwork by Gabriele Wölke and Matthias Birk is highly acknowledged.

EGEA

Coordination : V Siroux (epidemiology, PI since 2013); F Demenais (genetics); I Pin (clinical aspects); R Nadif (biology); F Kauffmann (PI 1992-2012).

Respiratory epidemiology : Inserm U 700, Paris : M Korobaeff (Egea1), F Neukirch (Egea1); Inserm U 707, Paris : I Annesi-Maesano (Egea1-2) ; Inserm CESP/U 1018, Villejuif : F Kauffmann, N Le Moual, R Nadif, MP Oryszczyn (Egea1-2), R Varraso ; Inserm U 823, Grenoble : V Siroux.

Genetics : Inserm U 393, Paris : J Feingold ; Inserm U 946, Paris : E Bouzigon, F Demenais, MH Dizier ; CNG, Evry : I Gut (now CNAG, Barcelona, Spain), M Lathrop (now Univ McGill, Montreal, Canada).

Clinical centers : Grenoble : I Pin, C Pison; Lyon : D Ecochard (Egea1), F Gormand, Y Pacheco ; Marseille : D Charpin (Egea1), D Vervloet (Egea1-2) ; Montpellier : J Bousquet ; Paris Cochin : A Lockhart (Egea1), R Matran (now in Lille) ; Paris Necker : E Paty (Egea1-2), P Scheinmann (Egea1-2) ; Paris-Trousseau : A Grimfeld (Egea1-2), J Just.

Data and quality management : Inserm ex-U155 (Egea1) : J Hochez ; Inserm CESP/U 1018, Villejuif : N Le Moual; Inserm ex-U780 : C Ravault (Egea1-2) ; Inserm ex-U794 : N Chateigner (Egea1-2) ; Grenoble: J Quentin-Ferran (Egea1-2).

NHSD

We acknowledge the NSHD participants and the NSHD scientific and data collection teams.

SALIA

During the last decades a lot of scientist, study nurses and laboratories were involved in conducting the study. As representatives for all these people we would like to thank especially Reinhard Dolgner (MD) for organizing the baseline study and Barbara Schulten as study nurse for her help in organizing the follow-up study. We are most grateful for all the women from the Ruhr area and from Borken who participated in the study during decades.

SAPALDIA

Study directorate: T Rochat (p), NM Probst Hensch (e/g), JM Gaspoz (c), N Künzli (e/exp), C Schindler (s).

Scientific team: JC Barthélémy (c), W Berger (g), R Bettschart (p), A Bircher (a), G Bolognini (p), O Brändli (p), C Brombach (n), M Brutsche (p), L Burdet (p), M Frey (p), U Frey (pd), MW Gerbase (p), D Gold (e/c/p), E de Groot (c), W Karrer (p), R Keller (p), B Knöpfli (p), B Martin (pa), D Miedinger (o), U Neu (exp), L Nicod (p), M Pons (p), F Roche (c), T Rothe (p), E Russi (p), P Schmid-Grendelmeyer (a), A Schmidt-Trucksäss (pa), A Turk (p), J Schwartz (e), D. Stolz (p), P Straehl (exp), JM Tschopp (p), A von Eckardstein (cc), E Zemp Stutz (e).

Scientific team at coordinating centers: M Adam (e/g), E Boes (g), PO Bridevaux (p), D Carballo (c), E Corradi (e), I Curjuric (e), J Dratva (e), A Di Pasquale (s), L Grize (s), D Keidel (s), S Kriemler (pa), A Kumar (g), M Imboden (g), N Maire (s), A Mehta (e), F Meier (e), H Phuleria (exp), E Schaffner (s), GA Thun (g) A Ineichen (exp), M Ragetti (e), M Ritter (exp), T Schikowski (e), G Stern (pd), M Tarantino (s), M Tsai (e), M Wanner (pa)

(a) allergology, (c) cardiology, (cc) clinical chemistry, (e) epidemiology, (exp) exposure, (g) genetic and molecular biology, (m) meteorology, (n) nutrition, (o) occupational health, (p) pneumology, (pa) physical activity, (pd) pediatrics, (s) statistics

The study could not have been done without the help of the study participants, technical and administrative support and the medical teams and field workers at the local study sites.

Local fieldworkers: Aarau: S Brun, G Giger, M Sperisen, M Stahel, Basel: C Bürli, C Dahler, N Oertli, I Harreh, F Karrer, G Novicic, N Wyttenbacher, Davos: A Saner, P Senn, R Winzeler, Geneva: F Bonfils, B Blicharz, C Landolt, J Rochat, Lugano: S Boccia, E Gehrig, MT Mandia, G Solari, B Viscardi, Montana: AP Bieri, C Darioly, M Maire, Payerne: F Ding, P Danieli A Vonnez, Wald: D Bodmer, E Hochstrasser, R Kunz, C Meier, J Rakic, U Schafroth, A Walder.

Administrative staff: C Gabriel, R Gutknecht.

References

1. Sunyer J. Lung function effects of chronic exposure to air pollution. *Thorax* 2009; **64**(8): 645-6.
2. Anderson JO, Thundiyil JG, Stolbach A. Clearing the air: a review of the effects of particulate matter air pollution on human health. *Journal of medical toxicology : official journal of the American College of Medical Toxicology* 2012; **8**(2): 166-75.
3. Gehring U, Gruzieva O, Agius RM, et al. Air Pollution Exposure and Lung Function in Children: The ESCAPE Project. *Environ Health Perspect* 2013.
4. Forbes LJ, Kapetanakis V, Rudnicka AR, et al. Chronic exposure to outdoor air pollution and lung function in adults. *Thorax* 2009; **64**(8): 657-63.
5. Ackermann-Lieblich U, Leuenberger P, Schwartz J, et al. Lung function and long term exposure to air pollutants in Switzerland. Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) Team. *American journal of respiratory and critical care medicine* 1997; **155**(1): 122-9.
6. Gotschi T, Heinrich J, Sunyer J, Kunzli N. Long-term effects of ambient air pollution on lung function: a review. *Epidemiology (Cambridge, Mass)* 2008; **19**(5): 690-701.
7. Schikowski T, Sugiri D, Ranft U, et al. Long-term air pollution exposure and living close to busy roads are associated with COPD in women. *Respiratory research* 2005; **6**: 152.
8. Downs SH, Schindler C, Liu LJ, et al. Reduced exposure to PM10 and attenuated age-related decline in lung function. *The New England journal of medicine* 2007; **357**(23): 2338-47.
9. Eckel SP, Louis TA, Chaves PH, Fried LP, Margolis AH. Modification of the association between ambient air pollution and lung function by frailty status among older adults in the Cardiovascular Health Study. *American journal of epidemiology* 2012; **176**(3): 214-23.
10. Eeftens M, Beelen R, de Hoogh K, et al. Development of Land Use Regression models for PM(2.5), PM(2.5) absorbance, PM(10) and PM(coarse) in 20 European study areas; results of the ESCAPE project. *Environmental science & technology* 2012; **46**(20): 11195-205.
11. Beelen R, Hoek G, Vienneau D, et al. Development of NO2 and NOx land use regression models for estimating air pollution exposure in 36 study areas in Europe - The ESCAPE project. *Atmos Environ* 2013; **72**: 10-23.
12. Beelen R, Raaschou-Nielsen O, Stafoggia M, et al. Effects of long-term exposure to air pollution on natural-cause mortality: an analysis of 22 European cohorts within the multicentre ESCAPE project. *Lancet* 2013.
13. Eeftens M, Tsai MY, Ampe C, et al. Spatial variation of PM2.5, PM10, PM2.5 absorbance and PMcoarse concentrations between and within 20 European study areas and the relationship with NO2 - Results of the ESCAPE project. *Atmos Environ* 2012; **62**: 303-17.
14. Cyrus J, Eeftens M, Heinrich J, et al. Variation of NO2 and NOx concentrations between and within 36 European study areas: Results from the ESCAPE study. *Atmos Environ* 2012; **62**: 374-90.
15. Gulliver J, de Hoogh K, Hansell A, Vienneau D. Development and back-extrapolation of NO2 land use regression models for historic exposure assessment in Great Britain. *Environmental science & technology* 2013; **47**(14): 7804-11.
16. Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. *The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology* 2007; **30**(4): 616-22.
17. Schikowski T, Schaffner E, Meier F, et al. Improved Air Quality and Attenuated Lung Function Decline: Modification by Obesity in the SAPALDIA Cohort. *Environ Health Perspect* 2013.
18. Jones RL, Nzekwu MM. The effects of body mass index on lung volumes. *Chest* 2006; **130**(3): 827-33.

19. Pistelli F, Bottai M, Carrozzi L, et al. Changes in obesity status and lung function decline in a general population sample. *Respiratory medicine* 2008; **102**(5): 674-80.
20. Mancuso P. Obesity and lung inflammation. *Journal of applied physiology* 2010; **108**(3): 722-8.
21. Dubowsky SD, Suh H, Schwartz J, Coull BA, Gold DR. Diabetes, obesity, and hypertension may enhance associations between air pollution and markers of systemic inflammation. *Environ Health Perspect* 2006; **114**(7): 992-8.
22. Madrigano J, Baccarelli A, Wright RO, et al. Air pollution, obesity, genes and cellular adhesion molecules. *Occupational and environmental medicine* 2010; **67**(5): 312-7.
23. Johnston RA, Theman TA, Lu FL, Terry RD, Williams ES, Shore SA. Diet-induced obesity causes innate airway hyperresponsiveness to methacholine and enhances ozone-induced pulmonary inflammation. *Journal of applied physiology* 2008; **104**(6): 1727-35.
24. Shore SA, Lang JE, Kasahara DI, et al. Pulmonary responses to subacute ozone exposure in obese vs. lean mice. *Journal of applied physiology* 2009; **107**(5): 1445-52.
25. Alexeeff SE, Litonjua AA, Suh H, Sparrow D, Vokonas PS, Schwartz J. Ozone exposure and lung function: effect modified by obesity and airways hyperresponsiveness in the VA normative aging study. *Chest* 2007; **132**(6): 1890-7.
26. Bennett WD, Hazucha MJ, Folinsbee LJ, Bromberg PA, Kissling GE, London SJ. Acute pulmonary function response to ozone in young adults as a function of body mass index. *Inhalation toxicology* 2007; **19**(14): 1147-54.
27. Gotschi T, Sunyer J, Chinn S, et al. Air pollution and lung function in the European Community Respiratory Health Survey. *International journal of epidemiology* 2008; **37**(6): 1349-58.
28. Gerbase MW, Dupuis-Lozeron E, Schindler C, et al. Agreement between Spirometers: A Challenge in the Follow-Up of Patients and Populations? *Respiration* 2013; **85**(6): 505-14.
29. Basagana X, Rivera M, Aguilera I, et al. Effect of the number of measurement sites on land use regression models in estimating local air pollution. *Atmos Environ* 2012; **54**: 634-42.
30. Wang M, Beelen R, Eeftens M, Meliefste K, Hoek G, Brunekreef B. Systematic Evaluation of Land Use Regression Models for NO₂. *Environmental science & technology* 2012; **46**(8): 4481-9.

Table 1. Description of cohort-specific study populations. Characteristics ^a are presented for the larger subgroup of participants included in the analysis of NO₂ and NO_x and traffic indicators (Characteristics for the smaller subgroup of participants included in the PM metrics analyses are presented in Supplemental Table 1).

Study	ECRHS		EGEA		NSHD		SALIA		SAPALDIA	
	N _{total} =3859		N _{total} =568		N _{total} =844		N _{total} =580		N _{total} =1764	
1 st spirometry	1991-1993		1991-1995		1999		1985-1994		1991-1992	
2 nd spirometry	2001-2002		2003-2007		2006-2010		2007-2009		2002	
Characteristics	N/mean	%/SD	N/mean	%/SD	N/mean	%/SD	N/mean	%/SD	N/mean	%/SD
Female	1981	51.3%	303	53.3%	471	55.8%	580	100.0%	980	55.6%
Age	43.0	7.2	53.1	11.3	63.3	1.1	73.3	3.4	53.2	11.0
BMI [kg/m ³]	25.7	4.6	25.3	4.3	27.7	4.9	27.4	4.5	25.4	4.3
Height [in cm]	168.6	9.5	168.5	8.4	167.4	8.6	162.3	5.5	168.8	9.0
Exsmoker	1064	27.6%	206	36.3%	497	58.9%	99	17.1%	568	32.2%
Current smoker	1224	31.7%	81	14.3%	77	9.1%	18	3.1%	492	27.9%
Pack years at 1 st spirometry ^b	7.7	12.0	5.9	10.0	9.1	12.6	2.8	8.4	10.9	17.9
Pack years from 1 st to 2 nd spirometry ^b	3.9	10.9	1.7	8.3	0.7	2.5	0.6	6.7	3.1	6.5
Medium educational level ^b	1321	34.2%	118	20.8%	439	52.0%	276	47.6%	1121	63.5%
High educational level ^b	1420	36.8%	263	46.3%	102	12.1%	199	34.3%	520	29.5%
Environmental tobacco exposure at home or at work ^b	676	17.5%	233	41.0%	168	19.9%	347	59.8%	119	6.7%
Occupational exposure to dust/fumes or gases ^b	1685	43.7%	125	22.0%	246	29.1%	39	6.7%	460	26.1%
Ever asthma ^{b,c}	616	16.0%	183	32.2%	83	9.8%	50	8.6%	155	8.8%
FEV ₁ [L]	3.47	0.81	3.03	0.85	2.83	0.66	2.20	0.42	3.10	0.82
FVC [L]	4.33	0.10	4.00	1.01	3.57	0.81	2.91	0.54	4.08	1.02
change of FEV ₁ [L] ^d	-0.026	0.032	-0.028	0.031	-0.022	0.025	-0.020	0.014	-0.033	0.030
change of FVC [L] ^d	-0.018	0.040	-0.015	0.037	-0.025	0.034	-0.022	0.019	-0.022	0.041

The table shows the amount of observations (N, and % of total N) for categorical variables, and the mean value (and standard deviation (SD)) in case of continuous variables. ^a Characteristics refer to time point of 2nd spirometry. ^b Information missing on a limited number of subjects. ^c Asthma diagnosed by a physician at 1st and/or at 2nd spirometry. ^d Change in lung function between 1st and 2nd spirometry.

Table 2

Distribution of all exposure estimates (annual averages of ambient air pollutants and traffic indicators), at participants residential addresses in each cohort.

Cohorts	ECRHS			EGEA			NSHD			SALIA			SAPALDIA		
	N	Mean	IQR	N	Mean	IQR	N	Mean	IQR	N	Mean	IQR	N	Mean	IQR
Exposures															
PM _{2.5} [$\mu\text{g}/\text{m}^3$]	1830	15.9	7.0	342	15.3	2.0	751	9.5	1.5	580	17.8	1.7	729	16.8	1.1
PM _{2.5} absorbance [10^{-5}m^{-1}]	1540	2.0	1.6	148	2.1	1.3	751	1.0	0.3	580	1.4	0.4	729	1.9	0.5
PM ₁₀ [$\mu\text{g}/\text{m}^3$]	1830	25.8	9.7	342	25.1	4.0	751	15.7	1.9	580	26.7	2.1	729	23.2	2.3
PM _{coarse} [$\mu\text{g}/\text{m}^3$]	1830	10.3	4.7	342	9.4	3.3	751	6.4	0.8	580	9.4	1.6	729	6.5	1.9
NO ₂ [$\mu\text{g}/\text{m}^3$]	3859	28.9	18.7	568	27.4	14.7	844	22.4	10.0	580	27.6	8.1	1764	27.0	7.7
NO _x [$\mu\text{g}/\text{m}^3$]	3859	50.5	34.5	568	46.7	27.9	844	37.5	17.1	580	44.2	20.7	1764	44.8	15.2
Traffic intensity on nearest road [cars/day]	2492	4807	5509	568	6633	6667	844	1239	0	580	1642	0	1697	3207	3876
Traffic load on nearest major road [cars-km/day; in thousand] ^a	2687	1.45	1.67	568	1.37	1.58	844	0.27	0	580	0.72	0.32	1671	0.94	1.42
NO ₂ (backextrapolated to 1 st spirometry) [$\mu\text{g}/\text{m}^3$]	_b	_b	_b	_b	_b	_b	841	26.3	11.2	580	36.0	14.0	1762	47.7	12.3
PM ₁₀ (backextrapolated to 1 st spirometry) [$\mu\text{g}/\text{m}^3$]	_b	_b	_b	_b	_b	_b	748	22.0	2.6	580	47.7	13.6	726	46.2	4.0
NO ₂ (backextrapolated to 2 nd spirometry) [$\mu\text{g}/\text{m}^3$]	3859	34.2	23.0	568	32.1	17.5	- ^c	1764	31.0	8.0					
PM ₁₀ (backextrapolated to 2 nd spirometry) [$\mu\text{g}/\text{m}^3$]	1388	27.1	8.4	148	27.0	5.3	- ^c	729	37.8	4.3					

PM_{2.5}: particulate matter with a diameter of 2.5 micrometers or less; PM_{2.5}abs: absorbance of particulate matter with a diameter of 2.5 micrometers; PM₁₀: particulate matter with a diameter of 10 micrometers or less; PM_{coarse}: coarse fraction of PM_{2.5} to PM₁₀; NO₂: nitrogen dioxide; NO_x: nitrogen oxides. ^aTraffic load on nearest major road within a 100m buffer presented in thousands. ^bNo complete exposure backextrapolation to 1st spirometry available. ^cNo backextrapolation applied as time point of 2nd spirometry coincides with time point of ESCAPE monitoring campaign.

Table 3:


Results of meta-analyses for the association ^a between level (upper part of table) and change (lower part of table) of lung function and exposure to air pollution and traffic intensity indicators.

Level of lung function ^b	FEV ₁ (in mL)			FVC (in mL)		
	beta ^c	95%CI	I ² f p-value _{het}	beta ^c	95%CI	I ² f p-value _{het}
NO ₂ (10 µg/m ³)	-13.98	-25.82 to -2.14	0.0% p=0.625	-14.93	-28.73 to -1.13	0.0% p=0.977
NO _x (20 µg/m ³)	-12.91	-23.79 to -2.04	0.0% p=0.861	-13.25	-25.85 to -0.65	0.0% p=0.962
PM ₁₀ (10 µg/m ³)	-44.56	-85.36 to -3.76	0.0% p=0.628	-58.96	-112.27 to -5.65	0.0% p=0.785
PM _{2.5} (5 µg/m ³)	-21.14	-56.37 to 14.08	0.0% p=0.535	-36.39	-83.29 to 10.5	0.0% p=0.877
PM _{2.5} absorbance (10 ⁻⁵ m ⁻¹)	-24.40	-55.58 to 6.79	0.0% p=0.709	-12.94	-50.23 to 24.3	0.0% p=0.619
PM _{coarse} (5 µg/m ³)	-22.36	-94.00 to 49.27	12.6% p=0.333	2.88	-87.85 to 93.6	0.0% p=0.760
Traffic intensity on nearest road ^e	-27.61	-59.62 to 4.39	29.0% p=0.228	-10.37	-48.23 to 27.49	27.3% p=0.239
Traffic load on nearest major road in a 100m buffer ^e	-32.34	-59.30 to -5.38	0.0% p=0.784	-18.64	-50.22 to 12.94	0.0% p=0.967
Change in lung function	FEV ₁ (in mL/year)			FVC (in mL/year)		
Exposure	beta ^d	95%CI	I ² f p-value _{het}	beta ^d	95%CI	I ² f p-value _{het}
NO ₂ (10 µg/m ³)	0.30	-0.39 to 0.98	0.0% p=0.681	0.02	-0.84 to 0.88	0.0% p=0.532
NO _x (20 µg/m ³)	0.18	-0.44 to 0.80	0.0% p=0.708	-0.09	-0.86 to 0.69	0.0% p=0.804
PM ₁₀ (10 µg/m ³)	-0.39	-2.85 to 2.06	53.1% p=0.074%	-1.42	-4.53 to 1.70	28.4% p=0.232
PM _{2.5} (5 µg/m ³)	-0.14	-2.26 to 1.98	23.8% p=0.263	-1.37	-4.04 to 1.29	0.0% p=0.964
PM _{2.5} absorbance (10 ⁻⁵ m ⁻¹)	0.88	-0.76 to 2.52	54.5% p=0.066	1.14	-0.95 to 3.24	4.5% p=0.381
PM _{coarse} (5 µg/m ³)	0.26	-3.92 to 4.43	61.7% p=0.034	-1.31	-6.49 to 3.88	0.0% p=0.506
Traffic intensity on nearest road ^e	-0.74	-2.58 to 1.10	0.0% p=0.772	-0.15	-2.49 to 2.18	18.1% p=0.299
Traffic load on nearest major road in a 100m buffer ^e	-0.32	-1.81 to 1.18	0.0% p=0.987	0.34	-1.56 to 2.25	0.0% p=0.672

^aAssociations are presented for the following increments in exposure: 10 µg/m³ for NO₂, 20 µg/m³ for NO_x, 1*10⁻⁵m⁻¹ for PM_{2.5} absorbance, 5 µg/m³ for PM_{2.5}, 10 µg/m³ for PM₁₀, 5 µg/m³ for PM_{coarse}, traffic intensity on the nearest street (2 categories: low ≤5000 and high>5000 [cars/day]); and for traffic load on major roads within a 100 m buffer (2 categories: low ≤ 500 and high>500 [cars-km/day]). ^b Level of lung function for cross-sectional analysis was derived from 2nd spirometry. ^c The betas for the association between level of lung function and exposure, are adjusted for age, age squared, height, sex, BMI, highest educational level, and smoking status at 2nd spirometry; a negative sign indicates lower lung function with increasing exposure. ^d the betas of the association between change in lung function and exposure, are adjusted for sex, age and height at 1st spirometry, highest educational level, smoking at 1st spirometry, smoking cessation and change in BMI to the 2nd spirometry; a negative sign indicates steeper lung function decline with increasing exposure. ^e associations with traffic intensity (2 categories: low ≤5000 and high>5000 [cars/day]) and traffic load (2 categories: low ≤ 500 and high>500 [cars-km/day]) were additionally adjusted for background NO₂ concentrations. ^f I² and Cochran's test for heterogeneity of effect estimates between cohorts.

Figure 1 and Figure 2


Forest plot displaying the study-specific mixed linear regression model estimates ^{a,b} of the association of NO₂ with **level of lung function (FEV₁; FVC; in mL)** (Based on all study participants living in sites with ESCAPE models available).



NO_{2_1} indicates NO₂ measured at time of ESCAPE. ^a Associations with lung function measures are presented as increments in NO₂ per 10µg/m³. I-square: variation in estimated effects attributable to heterogeneity. D+L (**D**er Simonian and **L**aird method): pooled estimate of all studies. ^b The mixed linear regression models were adjusted for: age, age squared, height, sex, BMI, highest educational level, and smoking status at 2nd spirometry; negative estimates indicated lower lung function with increasing exposure.

Figure 3 and Figure 4

Forest plot displaying the study-specific mixed linear regression model estimates ^{a,b} of the association of NO₂ with level of FEV₁(in mL) **stratified by obesity status** ^c.



NO_{2_1} indicates NO₂ measured at time of ESCAPE. ^a Associations with lung function measures are presented as increments in NO₂ per 10µg/m³. I-square: variation in estimated effects attributable to heterogeneity. D+L (Der Simonian and Laird method): pooled estimate of all studies. ^b The mixed linear regression models were adjusted for: age, age squared, height, sex, BMI, highest educational level, and smoking status at 2nd spirometry; negative estimates indicated lower lung function with increasing exposure. ^c Obesity has been stratified as not obese “BMI<30 kg/m²” and obese “BMI≥30 kg/m²”. P-value for heterogeneity obese vs. non-obese: 0.098 for FEV₁.